



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

AGK2

Cat. No.:	HY-100578
CAS No.:	304896-28-4
Molecular Formula:	C ₂₃ H ₁₃ Cl ₂ N ₃ O ₂
Molecular Weight:	434.27
Target:	Sirtuin; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Epigenetics; Apoptosis
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months



SOLVENT & SOLUBILITY

In Vitro	DMSO : 12.5 mg/mL (28.78 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.3027 mL	11.5136 mL	23.0271 mL
		5 mM		0.4605 mL	2.3027 mL	4.6054 mL
		10 mM		0.2303 mL	1.1514 mL	2.3027 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.5 mg/mL (1.15 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.5 mg/mL (1.15 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.5 mg/mL (1.15 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	AGK2 is a selective SIRT2 inhibitor with an IC ₅₀ of 3.5 μM. AGK2 inhibits SIRT1 and SIRT3 with IC ₅₀ s of 30 and 91 μM, respectively.		
IC ₅₀ & Target	SIRT2 3.5 μM (IC ₅₀)	SIRT1 30 μM (IC ₅₀)	SIRT3 91 μM (IC ₅₀)
In Vitro	AGK2 significantly inhibits cell proliferation in a dose-dependent manner. AGK2 also significantly inhibits cell growth in a		

dose-dependent manner without inducing cytotoxicity at low doses. Twelve days after AGK2 (5 μ M) treatment, cells show a significantly reducing colony forming ability in soft agar to 46% of the control cells. Western blot analysis shows that the levels of CDK4 or CDK6 and cyclin D1 are decreased after AGK2 treatment in a dose-dependent manner. In addition, AGK2 inhibits the expression of p53 protein^[2]. Treatment of microglial BV2 cells with 10 μ M AGK2 leads to a significant increase in PAR signals. Treatment of microglial BV2 cells with 10 μ M AGK2 also leads to a significant decrease in the intracellular ATP and significant increases in both late-stage apoptosis and necrosis of the cells^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AGK2 significantly reduces mortality and decreases levels of cytokines in blood (TNF- α : 298.3 $\pm$ 24.6 vs 26.8 $\pm$ 2.8 pg/mL, p =0.0034; IL-6: 633.4 $\pm$ 82.8 vs 232.6 $\pm$ 133.0 pg/mL, p =0.0344) and peritoneal fluid (IL-6: 704.8 $\pm$ 67.7 vs 391.4 $\pm$ 98.5 pg/mL, p =0.033) compare to vehicle control. AGK2 also suppresses the TNF- α and IL-6 production in the culturing splenocytes (TNF- α : 68.1 $\pm$ 6.4 vs 23.9 $\pm$ 2.8 pg/mL, p =0.0009; IL-6: 73.1 $\pm$ 4.2 vs 49.6 $\pm$ 3.0 pg/mL; p =0.0051)^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[2]

Cells are exposed to different concentrations of AGK2 in 1 mL of 0.3% basal medium agar containing 10% FBS. The cultures are maintained at 37°C in a 5% CO₂ incubator for 10-15 days, and the cell colonies are scored using an inverted microscope ^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[4]

Mice are intraperitoneally given either AGK2 (82 mg/kg) in dimethyl sulfoxide (DMSO) or DMSO alone, and 2 h later subjects to CLP. Survival is monitored for 240 hours. AGK2-treating mice are grouped into (i) DMSO vehicle, and (ii) AGK2, with sham mice (operating but without any treatment) serving as controls. Peritoneal fluid and peripheral blood are examined at 24 and 48 hours for cytokine production^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Acta Pharm Sin B. 2019 Dec 13;8(12):1421-1428.
- Acta Pharm Sin B. 2019 Nov;9(6):1183-1192.
- Theranostics. 2021 Feb 25;11(9):4381-4402.
- iScience. 2020 Aug 21;23(8):101431.
- Int Immunopharmacol. 2022 Jun 28;110:109000.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Tatum PR, et al. Identification of novel SIRT2-selective inhibitors using a click chemistry approach. *Bioorg Med Chem Lett*. 2014 Apr 15;24(8):1871-4.
- [2]. Kim HW, et al. Sirtuin inhibitors, EX527 and AGK2, suppress cell migration by inhibiting HSF1 protein stability. *Oncol Rep*. 2016 Jan;35(1):235-42.
- [3]. Li Y, et al. Poly(ADP-ribose) polymerase mediates both cell death and ATP decreases in SIRT2 inhibitor AGK2-treated microglial BV2 cells. *Neurosci Lett*. 2013 Jun 7;544:36-40.
- [4]. Zhao T, et al. Selective Inhibition of SIRT2 Improves Outcomes in a Lethal Septic Model. *Curr Mol Med*. 2015;15(7):634-41.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA